Emerging role of IL-6 and NLRP3 inflammasome as potential therapeutic targets to combat COVID-19: Role of lncRNAs in cytokine storm modulation.

Szczegóły
Abstrakt

Tytuł:: Emerging role of IL-6 and NLRP3 inflammasome as potential therapeutic targets to combat COVID-19: Role of lncRNAs in cytokine storm modulation.
Autorzy:: Paniri A; Student Research Committee, Babol University of Medical Sciences, Babol, Iran; Genetics Department, Faculty of Medicine, Babol University of Medical Sciences, Babol, Iran.
Akhavan-Niaki H; Genetics Department, Faculty of Medicine, Babol University of Medical Sciences, Babol, Iran; Zoonoses Research Center, Pasteur Institute of Iran, Amol, Iran. Electronic address: .
Źródło:: Life sciences [Life Sci] 2020 Sep 15; Vol. 257, pp. 118114. Date of Electronic Publication: 2020 Jul 18.
Typ publikacji:: Journal Article; Review
Język:: English
Imprint Name(s):: Publication: <2008->: Amsterdam : Elsevier
Original Publication: Oxford; Elmsford, N. Y. [etc.] Pergamon Press.
MeSH Terms:: Betacoronavirus/*genetics
Coronavirus Infections/*immunology
Interleukin-6/*immunology
Pneumonia, Viral/*immunology
RNA, Long Noncoding/*physiology
Anti-Inflammatory Agents/pharmacology ; Betacoronavirus/immunology ; Betacoronavirus/metabolism ; COVID-19 ; Coronavirus Infections/metabolism ; Cytokines/genetics ; Cytokines/immunology ; Humans ; Inflammasomes/immunology ; Inflammation/immunology ; Interleukin-6/metabolism ; Interleukin-6/pharmacology ; NLR Family, Pyrin Domain-Containing 3 Protein/immunology ; Pandemics ; Pneumonia, Viral/metabolism ; RNA, Long Noncoding/genetics ; SARS-CoV-2
References:: Int J Mol Sci. 2019 Nov 28;20(23):. (PMID: 31795299)
J Clin Endocrinol Metab. 2003 Feb;88(2):528-30. (PMID: 12574174)
Connect Tissue Res. 2018 Nov;59(6):581-592. (PMID: 29649906)
Arch Biochem Biophys. 2018 Jul 1;649:15-21. (PMID: 29704485)
Biomed Pharmacother. 2018 Jul;103:897-902. (PMID: 29710506)
J Exp Clin Cancer Res. 2015 Oct 09;34:116. (PMID: 26452542)
Nature. 2015 Mar 5;519(7541):57-62. (PMID: 25731159)
Biochem Pharmacol. 2019 Nov;169:113638. (PMID: 31518552)
Nature. 2006 May 11;441(7090):235-8. (PMID: 16648838)
Biochem Pharmacol. 2013 May 15;85(10):1504-12. (PMID: 23506741)
Cytokine Growth Factor Rev. 2020 Jun;53:13-24. (PMID: 32475759)
PLoS Pathog. 2014 May 01;10(5):e1004077. (PMID: 24788150)
Cell Host Microbe. 2016 Feb 10;19(2):181-93. (PMID: 26867177)
Semin Arthritis Rheum. 2015 Dec;45(3):341-50. (PMID: 26228647)
Int J Antimicrob Agents. 2020 May;55(5):105954. (PMID: 32234467)
Cancer Manag Res. 2019 Apr 08;11:2729-2737. (PMID: 31114330)
Zhonghua Bing Li Xue Za Zhi. 2020 May 8;49(5):411-417. (PMID: 32172546)
Virol Sin. 2020 Jun;35(3):266-271. (PMID: 32125642)
Ren Fail. 2018 Nov;40(1):527-533. (PMID: 30277425)
Mol Cancer. 2018 Jan 31;17(1):18. (PMID: 29386037)
Ann Rheum Dis. 2012 Oct;71(10):1630-5. (PMID: 22966146)
Immunol Rev. 2015 May;265(1):205-16. (PMID: 25879295)
J Clin Invest. 2013 Feb;123(2):767-81. (PMID: 23321674)
Int Immunopharmacol. 2020 Feb 19;82:106317. (PMID: 32087497)
J Hepatol. 2016 Jun;64(6):1403-15. (PMID: 26867490)
Mol Cancer Ther. 2012 May;11(5):1112-21. (PMID: 22402124)
Nat Rev Immunol. 2018 Dec;18(12):773-789. (PMID: 30254251)
Shock. 2006 Jul;26(1):10-2. (PMID: 16783191)
Biomed Pharmacother. 2019 Oct;118:109222. (PMID: 31351424)
Int J Clin Exp Pathol. 2019 Mar 01;12(3):941-948. (PMID: 31933904)
J Med Chem. 2017 May 11;60(9):3656-3671. (PMID: 28410442)
Virology. 2015 Nov;485:330-9. (PMID: 26331680)
Nat Commun. 2012 Jan 17;3:630. (PMID: 22252554)
J Exp Clin Cancer Res. 2019 Sep 18;38(1):411. (PMID: 31533774)
J Rheumatol. 2003 Jul;30(7):1426-35. (PMID: 12858437)
Cell Death Dis. 2019 Jun 26;10(7):503. (PMID: 31243263)
Int Immunopharmacol. 2017 Jun;47:134-140. (PMID: 28391160)
Cell Prolif. 2019 Jan;52(1):e12525. (PMID: 30362186)
Front Microbiol. 2019 Jan 29;10:50. (PMID: 30761102)
Mediators Inflamm. 2013;2013:370804. (PMID: 23935248)
Inflammation. 2019 Aug;42(4):1139-1146. (PMID: 30825076)
EMBO J. 1987 Oct;6(10):2939-45. (PMID: 3500852)
Sci Rep. 2017 Nov 8;7(1):15020. (PMID: 29118366)
Clin Infect Dis. 2020 Nov 5;71(8):1937-1942. (PMID: 32301997)
Nat Med. 2015 Mar;21(3):248-55. (PMID: 25686105)
Clin Med Insights Arthritis Musculoskelet Disord. 2012;5:27-42. (PMID: 22438671)
Infect Genet Evol. 2020 Sep;83:104327. (PMID: 32320825)
Lancet. 2020 Feb 22;395(10224):e35-e36. (PMID: 32035018)
PLoS One. 2016 Mar 01;11(3):e0150018. (PMID: 26930607)
Biomed Pharmacother. 2018 Apr;100:240-249. (PMID: 29432995)
Virus Res. 2009 Jun;142(1-2):19-27. (PMID: 19185596)
Circulation. 1995 Nov 15;92(10):3105-12. (PMID: 7586282)
Cell Death Dis. 2017 Feb 2;8(2):e2583. (PMID: 28151474)
Genome Med. 2015 May 13;7(1):39. (PMID: 25991924)
J Med Virol. 2020 Jul;92(7):791-796. (PMID: 32181911)
Trends Biochem Sci. 2016 Dec;41(12):1012-1021. (PMID: 27669650)
Nat Rev Cardiol. 2018 Apr;15(4):203-214. (PMID: 29143812)
Mediators Inflamm. 2015;2015:387842. (PMID: 26424968)
Am J Cancer Res. 2018 Jul 01;8(7):1176-1189. (PMID: 30094092)
J Pharmacol Sci. 2017 Oct;135(2):89-95. (PMID: 29056256)
Int J Cardiol. 2018 Mar 1;254:50. (PMID: 29407129)
Nat Immunol. 2012 Mar 19;13(4):333-42. (PMID: 22430786)
Tumour Biol. 2016 Nov;37(11):14895-14902. (PMID: 27644247)
Cell Mol Immunol. 2016 Mar;13(2):148-59. (PMID: 26549800)
Nat Rev Clin Oncol. 2018 Apr;15(4):234-248. (PMID: 29405201)
Nat Immunol. 2017 Mar 22;18(4):374-384. (PMID: 28323260)
J Cell Biol. 2009 Oct 5;187(1):61-70. (PMID: 19805629)
Mol Oncol. 2019 Nov;13(11):2344-2360. (PMID: 31246342)
J Immunol. 2003 Dec 15;171(12):6329-33. (PMID: 14662828)
Ann Rheum Dis. 2009 Jul;68(7):1235-6. (PMID: 19525413)
J Biol Regul Homeost Agents. 2020 Mar 14;34(2):327-331. (PMID: 32171193)
Semin Immunopathol. 2017 Jul;39(5):529-539. (PMID: 28466096)
J Thorac Dis. 2018 Sep;10(Suppl 26):S3084-S3087. (PMID: 30370085)
Br J Cancer. 2010 Oct 12;103(8):1154-62. (PMID: 20808314)
Nat Rev Immunol. 2005 Dec;5(12):917-27. (PMID: 16322745)
Front Immunol. 2019 Oct 25;10:2538. (PMID: 31749805)
Elife. 2016 Mar 24;5:e13663. (PMID: 27011353)
Annu Rev Immunol. 2011;29:707-35. (PMID: 21219188)
Biosci Rep. 2017 Dec 11;38(2):. (PMID: 29229673)
J Cell Physiol. 2018 Sep;233(9):6679-6688. (PMID: 29215698)
ACS Chem Neurosci. 2017 Oct 18;8(10):2194-2201. (PMID: 28653829)
Arthritis Rheumatol. 2016 Nov;68(11):2575-2583. (PMID: 27214788)
Med (N Y). 2020 Dec 18;1(1):105-113.e4. (PMID: 32838353)
Clin Immunol. 2020 Jun;215:108448. (PMID: 32353634)
Front Genet. 2018 Oct 15;9:471. (PMID: 30374364)
J Allergy Clin Immunol. 2020 Jul;146(1):128-136.e4. (PMID: 32425269)
Nat Immunol. 2015 May;16(5):448-57. (PMID: 25898198)
Resuscitation. 2012 Jul;83(7):907-12. (PMID: 22245750)
Ecancermedicalscience. 2020 Mar 27;14:1022. (PMID: 32256705)
Inflammation. 2020 Jun;43(3):1065-1076. (PMID: 32008164)
Am J Pathol. 2015 Jan;185(1):17-25. (PMID: 25451151)
Onco Targets Ther. 2017 Dec 05;10:5783-5794. (PMID: 29255366)
Blood. 2008 Nov 15;112(10):3959-64. (PMID: 18784373)
Nat Rev Drug Discov. 2018 Aug;17(8):588-606. (PMID: 30026524)
J Infect. 2020 Jun;80(6):607-613. (PMID: 32283152)
Biochimie. 2019 Feb;157:102-110. (PMID: 30347231)
Turk J Med Sci. 2020 Apr 17;50(SI-1):620-632. (PMID: 32299202)
Virus Res. 2007 Sep;128(1-2):1-8. (PMID: 17532082)
Stem Cells. 2006 May;24(5):1302-14. (PMID: 16357344)
Front Genet. 2012 Feb 27;3:25. (PMID: 22375145)
Mol Cell. 2002 Aug;10(2):417-26. (PMID: 12191486)
J Virol. 2008 Nov;82(22):11318-30. (PMID: 18753196)
Cell Commun Signal. 2018 Sep 5;16(1):55. (PMID: 30185178)
J Autoimmun. 2020 Jul;111:102452. (PMID: 32291137)
Rheumatol Int. 2014 May;34(5):711-6. (PMID: 23595570)
J Biol Chem. 2010 Mar 26;285(13):9792-9802. (PMID: 20093358)
J Cardiovasc Pharmacol. 2014 Apr;63(4):316-322. (PMID: 24336017)
J Biol Chem. 1996 Jan 12;271(2):736-41. (PMID: 8557680)
Curr Opin Immunol. 2007 Dec;19(6):615-22. (PMID: 17977705)
Aging (Albany NY). 2014 Dec;6(12):992-1009. (PMID: 25543668)
Eur J Immunol. 2010 Jul;40(7):1830-5. (PMID: 20583029)
Proc Natl Acad Sci U S A. 2018 Feb 13;115(7):E1530-E1539. (PMID: 29378952)
Diseases. 2016 Jul 25;4(3):. (PMID: 28933406)
Med Mal Infect. 2020 Jun;50(4):382-383. (PMID: 32259560)
Ther Deliv. 2015 Mar;6(3):283-95. (PMID: 25853305)
Ann Rheum Dis. 2014 Sep;73(9):1626-34. (PMID: 24297381)
FASEB J. 2019 Aug;33(8):8865-8877. (PMID: 31034780)
Cell Death Discov. 2019 Jun 5;5:101. (PMID: 31231549)
Med Sci Monit. 2019 Oct 26;25:8019-8024. (PMID: 31653823)
Sci Rep. 2018 Oct 23;8(1):15670. (PMID: 30353135)
Int J Mol Sci. 2019 Jul 06;20(13):. (PMID: 31284572)
Mutat Res Rev Mutat Res. 2014 Oct-Dec;762:1-21. (PMID: 25485593)
J Med Virol. 2020 Apr;92(4):424-432. (PMID: 31981224)
Cell Death Differ. 2019 Jan;26(1):130-145. (PMID: 29666475)
J Clin Invest. 2005 Aug;115(8):2047-58. (PMID: 16075046)
Nat Rev Immunol. 2020 Jun;20(6):363-374. (PMID: 32346093)
Med Sci Monit. 2019 Oct 11;25:7624-7633. (PMID: 31601776)
Nature. 2011 Jan 13;469(7329):221-5. (PMID: 21124315)
Nat Chem Biol. 2019 Jun;15(6):556-559. (PMID: 31086327)
J Virol. 2009 Jul;83(14):7062-74. (PMID: 19420084)
Front Immunol. 2020 May 19;11:1021. (PMID: 32574259)
J Hepatol. 2016 Jun;64(6):1283-94. (PMID: 26812074)
Curr Opin Immunol. 2018 Dec;55:9-14. (PMID: 30248523)
Clin Immunol. 2020 May;214:108393. (PMID: 32222466)
Nat Commun. 2019 Apr 2;10(1):1495. (PMID: 30940803)
J Biol Chem. 2017 Jul 28;292(30):12375-12382. (PMID: 28615453)
J Gen Virol. 2013 Dec;94(Pt 12):2679-2690. (PMID: 24077366)
J Cell Physiol. 2018 Sep;233(9):7103-7111. (PMID: 29633273)
J Surg Res. 2013 Aug;183(2):710-9. (PMID: 23558258)
Contributed Indexing:: Keywords: COVID-19; Cytokine release syndrome; Drug; Inflammasome; Inflammation; SARS-CoV-2
Substance Nomenclature:: 0 (Anti-Inflammatory Agents)
0 (Cytokines)
0 (Inflammasomes)
0 (Interleukin-6)
0 (NLR Family, Pyrin Domain-Containing 3 Protein)
0 (NLRP3 protein, human)
0 (RNA, Long Noncoding)
Entry Date(s):: Date Created: 20200722 Date Completed: 20200929 Latest Revision: 20230302
Update Code:: 20240104
PubMed Central ID:: PMC7368418
DOI:: 10.1016/j.lfs.2020.118114
PMID:: 32693241
: Czasopismo naukowe

Full Text Finder

The world has witnessed a high morbidity and mortality caused by SARS-CoV-2, and global death toll is still rising. Exaggerated inflammatory responses are thought to be more responsible for infiltrated immune cells accumulation, organ damage especially lung, dyspnea, and respiratory failure rather than direct effect of viral replication. IL-6 and NLRP3 inflammasome are the major immune components in immune responses stimulation upon pathogen infection. It's noteworthy that the function and expression of these components are remarkably influenced by non-coding RNAs including long non-coding RNAs. Given the potential role of these components in organ damage and pathological manifestations of patients infected with COVID-19, their blockage might be a hopeful and promising treatment strategy. Notably, more study on long non-coding RNAs involved in inflammatory responses could elevate the efficacy of anti-inflammatory therapy. In this review we discuss the potential impact of IL-6 and NLRP3 inflammasome blocker drugs on inflammatory responses, viral clearance, and pathological and clinical manifestations. Collectively, anti-inflammatory strategy might pave the way to diminish clinical and pathological manifestations and thereby discharging patients infected with COVID-19 from hospital.
Competing Interests: Declaration of competing interest Authors declare no conflict of interest.
(Copyright © 2020 Elsevier Inc. All rights reserved.)

Informacja